Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT180a in Haemophilia B
NCT03369444Phase 2Terminated
- Sponsor
- University College London
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 4
01
Overview
A Phase 2 trial of verbrinacogene setparvovec in hemophilia B (HB), sponsored by University College London. Started Dec 2017; status: terminated.
02
Drugs
verbrinacogene setparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03369444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369444.